Reflow Medical, Inc., a developer of innovative devices focused on cardiovascular disease, announces the first patient enrollments in “A pilot study of the Drug-Eluting Coronary Spur™ StEnt as a Primary trEatment for in-stent Restenosis (ISR) of the CORONARY arteries” (DEEPER CORONARY, NCT06117150). ISR is a common clinical problem that can generate significant health care costs and is often associated with an increased risk of death and rehospitalization. Known as the Coronary Sirolimus-Eluting Retrievable Scaffold System, or “Spur Elute,” this unique clinical solution is intended to treat patients with coronary ISR by transferring a proprietary sirolimus drug formulation to the diseased lesion without leaving a permanent metallic implant behind. The study is approved to enroll a total of 10 patients at up to three centers in New Zealand.

Principal Investigator Prof. Scott Harding, M.D., is an interventional cardiologist specializing in the treatment of complex coronary disease at Wellington Hospital in Wellington, New Zealand. He shared his experience with the Spur Elute, saying, “It’s exciting to take part in the study of this novel platform, which has the potential to successfully treat patients suffering from in-stent restenosis.”

William Lombardi, M.D., and Kathleen E. Kearney, M.D., interventional cardiologists at the UW Medicine Heart Institute in Seattle, Washington, were in attendance at the first enrollment. “Being able to deliver anti-proliferative drugs while maintaining blood flow can be a crucial element for treating ISR patients,” said Dr. Lombardi, who is the Director of the Complex Coronary Program at the Institute.

The Spur Elute is a novel device whose Retrievable Scaffold Therapy (RST) creates channels to increase uptake of antiproliferative drugs, while dilating the arterial lumen to maximize gain during the procedure. The system is then removed, without leaving anything behind.

“These enrollments take us one step closer to enabling physicians to utilize the Spur platform for treating patients with cardiovascular disease, and ISR in particular,” said Isa Rizk, CEO and Co-Founder of Reflow Medical, Inc. “We are so proud of the entire team and grateful to our external CRO, Mobius Medical, for reaching this milestone.” The pilot study of the Spur Elute for accessing and treating ISR follows last year’s successful introduction of the Reflow coraCatheters™ line for complex percutaneous coronary interventions (PCI).

About Reflow Medical, Inc.

Reflow Medical, Inc. focuses on empowering physicians through the design and development of innovative and effective technologies for cardiovascular disease. The Reflow portfolio includes products designed for use in treating cardiovascular disease in the coronary and peripheral vasculature.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240701117032/en/

Jennifer Carlyle
jcarlyle@reflowmedical.com
949-481-0399

Logo

Tags

More Like This

Reflow Medical Receives CE Mark for Bare Temporary Spur Stent System for Treating de novo or Restenotic Below-the-Knee (BTK) Lesions

Reflow Medical Expands Global Reach with New European Subsidiary

MedAlliance Announces Enrollment of over 1,660 Patients in Landmark SELUTION DeNovo Study

CONCEPT MEDICAL ANNOUNCES ENROLLMENT OF FIRST PATIENT IN "MAGICAL-ISR" IDE STUDY IN THE US

Corvia's RESPONDER-HF Confirmatory Trial Supported by RELIEVE-HF Data

Implantica announces first RefluxStop™ public tender win, paving the way for permanent reimbursement in Italy

Supira Medical Secures $120M Oversubscribed Series E Financing and Completes Enrollment of SUPPORT I Early Feasibility Study in the United States

Implantica's RefluxStop™ is now available in seven hospitals in Spain adding two new centers of excellence